Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -5 of 5
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
5/4/2005
 
First Published:
6/23/2004
1.
Phase I/II Study of Gimatecan in Patients With Recurrent or Progressive Primary Malignant Glioma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
18 and over
NCI, Pharmaceutical / Industry
UCLA-0403029-01
SIGMATAU-ST-01-402, NCT00087061
2.
A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
20 and over
Pharmaceutical / Industry
CLBQ707A1101
NCT00410358
3.
An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Biomarker/Laboratory analysis, Treatment
Closed
20 and over
Pharmaceutical / Industry
CLBQ707A1101E1
NCT00441610
4.
Extension to Dose-Escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
Pharmaceutical / Industry
CLBQ707A2101E1
NCT00462163
5.
A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
20 and over
Pharmaceutical / Industry
CLBQ707A1103
NCT00487058
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute